Abstract 245P
Background
Currently, the ambiguous role of neutrophils (Nph) in renal cancer (RC), which is determined by their phenotype, is of considerable interest. TGF-β is able to change the expression of pro-inflammatory cytokines of Nph and their receptors, as well as stimulate the production of chemokines that attract Nph to the site of inflammation, thus forming a pro-tumor phenotype (N2). TGF-β in the tumor microenvironment induces the migration of the CD11b+ Nph population. CD11b provides adhesion, migration, degranulation of Nph. Therefore, the study was aimed at assessing the expression of the TGF-β gene, as well as CD11b receptors, by circulating Nph at different stages of RC.
Methods
The study included patients with stage I-II (n=20), stage III-IV (n=20) clear cell RC (Med 62 years) and 20 - control group (CG) (Med 60 years). The study was approved by the Ethics Committee of the IME&PС of UlSU (prot. No. 1, 01/15/2020). RNA was isolated from the fraction of peripheral blood Nph on SileksMagNA magnetic particles (Sileks, Russia). After isolation, a reverse transcription reaction was performed. Expression of the TGF-β gene was determined by quantitative reverse transcription PCR using primers (Evrogen, Russia). Immunophenotyping was performed using monoclonal antibodies to the surface antigen CD11b (Sorbent, Russia). The results were expressed as Med (Q1-Q3). Statistical processing was performed using the Statistica 13, using the Mann–Whitney U-test and the Spearman correlation coefficient (p<0.05).
Results
A significant increase in the expression of the TGF-β gene in Nph was found in patients with RC compared with the CG (0.07 (0.12-2.21) vs 0.05 (0.04-0.13), p=0, 008), and also depending on the stage: at I-II stages of RC 0.43 (0.09-1.21), at III-IV 1.91 (0.87-3.18) (p=0.05). A significant increase in the expression of CD11b on the surface of Nph was found in patients with RC 73.3±5.1% vs the CG 19.0±9.3% (p=0.001), while no relationship with the stage was found. A direct correlation was found between TGF-β and CD11b gene expression in Nph (r=0.48, p=0.01).
Conclusions
In RC, the affinity of circulating neutrophils to the tumor microenvironment increases. At the same time, the level of expression of the growth factor TGF-β increases in Nph.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract